The designation applies to a one-time intravenous gene therapy in early clinical development, as Affinia Therapeutics continues to enroll patients in the Phase I/II UPBEAT trial.
The FDA has granted orphan drug designation to AFTX-201 (Affinia Therapeutics; Waltham, MA), an investigational gene therapy, for the treatment of BAG3-associated dilated cardiomyopathy (BAG3-DCM), according to the company. The designation follows a recent FDA Fast Track designation for the same program.
Don’t miss out on hearing about our latest peer-reviewed articles, expert opinions, conference news, podcasts and more.
BAG3-DCM is a genetic form of dilated cardiomyopathy caused by mutations that reduce production of BAG3 protein in cardiomyocytes, leading to early-onset, progressive heart failure, impaired quality of life, and reduced survival despite current treatments. Based on published literature cited by the company, BAG3 mutations are estimated to account for 2.3–3.6% of DCM cases worldwide. No approved treatment currently addresses the underlying mechanism of the disease.
AFTX-201 is designed to deliver a functional BAG3 transgene using a proprietary, rationally designed adeno-associated virus capsid engineered for efficient cardiac transduction, administered as a single intravenous infusion. Affinia says the capsid is designed to achieve cardiac transduction at doses 5- to 10-fold lower than those used in traditional gene therapies employing conventional capsids such as AAV9 or AAVrh74.
In an animal model of BAG3-DCM, AFTX-201 increased cardiac BAG3 protein levels, completely restored cardiac function, reversed structural abnormalities characteristic of the disease, and was associated with a survival benefit, according to the company. These findings are preclinical, and clinical benefit has not yet been established in patients.
AFTX-201 is now being evaluated in the Phase I/II UPBEAT trial (NCT07426419), which is enrolling adults aged 18–55 years with BAG3-DCM who experience difficulties performing everyday physical activities because of heart failure. The study is recruiting at multiple sites across the US and Canada and is designed to assess the safety and efficacy of the therapy.
Hideo Makimura, MD, PhD, chief medical officer at Affinia Therapeutics, said AFTX-201 was designed to address the underlying cause of BAG3-DCM. He added that the UPBEAT trial was actively recruiting at multiple institutions as the company continued to progress the clinical program.
Affinia said it plans to continue the development of AFTX-201 through the UPBEAT trial. Clinical data will be needed to determine the therapy’s safety, tolerability, and potential benefit in patients with BAG3-DCM.
References
- Affinia Therapeutics. FDA Grants Orphan Drug Designation to Affinia Therapeutics’ AFTX-201 for the Treatment of BAG3-Associated Dilated Cardiomyopathy (DCM). Press release. July 22, 2026.
- A Study to Evaluate the Safety and Efficacy of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (UPBEAT). ClinicalTrials.gov identifier: NCT07426419.
Cite: FDA grants orphan drug designation to AFTX-201 gene therapy for BAG3-associated dilated cardiomyopathy. touchCARDIO. July 23, 2026.
Disclosure: This content was created by the touchCARDIO team utilizing AI as an editorial tool (ChatGPT (GPT-5.4) [Large language model]. https://chat.openai.com/chat). The content was developed and edited by human editors. No funding was received in the publication of this article.
Editor: Nicola Cartridge, Director of Content
